(S)-2-(Boc-氨)-3-(Fmoc-氨)丙酸 | 122235-70-5

• 物质功能分类: 生物化工 - 生化试剂 - 氨基酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: (S)-2-(Boc-氨)-3-(Fmoc-氨)丙酸
• 中文别名: Nα-Boc-Nβ-Fmoc-L-2,3-二氨基丙酸；叔丁氧羰基-DAP(氨基酸)；Boc-3-(Fmoc-氨基)-L-丙氨酸；NΑ-叔丁氧羰基-NΒ-芴甲氧羰基-L-2,3-二氨基丙酸；叔丁氧羰基-Dap(氨基酸)羟基；N-叔丁氧羰基-N'-芴甲氧羰基-L-2,3-二氨基丙酸
• 英文名称: Boc-Dap(Fmoc)-OH
• 英文别名: (2S)-3-(9H-fluoren-9-ylmethoxycarbonylamino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
• CAS: 122235-70-5
• 化学式: C₂₃H₂₆N₂O₆
• 分子量: 426.469
• InChiKey: MVWPBNQGEGBGRF-IBGZPJMESA-N

物化性质

• 沸点：
  652.5±55.0 °C(Predicted)
• 密度：
  1.263±0.06 g/cm3(Predicted)
• 溶解度：
  溶于0.3g/2ml二甲基甲酰胺。
• 稳定性/保质期：

  如果按照规格使用和储存，则不会分解，且未有已知危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2924299090
• WGK Germany：
  3
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H317,H319,H335
• 储存条件：
  请将贮藏器保持密封，并存放在阴凉干燥处。确保工作环境具有良好的通风或排气设施。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Boc-Dap(Fmoc)-OH
CAS-No. : 122235-70-5
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No 1272/2008
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
Caution - substance not yet tested completely.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : Boc-3-(Fmoc-amino)-L-alanine
Nα-Boc-Nβ-Fmoc-L-2,3-diaminopropionic acid
Formula : C23H26N2O6
Molecular Weight : 426,46 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (S)-2-(Boc-氨)-3-(Fmoc-氨)丙酸 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 生成 N'-芴甲氧羰基-L-2,3-二氨基丙酸
  参考文献：
  名称：

  用于开发多环肽库的非经典二硫键导向基序的设计和核糖体整合

  摘要：

  天然存在的富含二硫键的肽 (DRP) 的工程设计受到二硫键配对困难的严重阻碍。利用折叠导向基序和非经典的含硫醇氨基酸的新 DRP 易于折叠，具有预期的二硫键连接性，代表了一类用于开发肽配体和治疗剂的新型支架。然而，支架的有限多样性，特别是难以被核糖体翻译的非经典氨基酸[例如青霉胺(Pen)]的使用极大地阻碍了这些DRP的进一步开发和应用。这里，我们设计并合成了非经典的二硫醇基序，它们带有类似于 Pen 硫醇的空间位阻硫醇基团，以指导肽折叠成特定的双环和三环结构。这些双硫醇基序可以通过与遗传密码重编程集成的市售 PURE 系统以核糖体方式掺入肽中，这首次实现了具有两个非规范和正交二硫键的双环肽的体外表达。我们进一步构建了一个由mRNA编码的双环肽库，并成功筛选出对蛋白质具有纳摩尔亲和力的新型双环肽配体。因此，本研究提供了一种新的、通用的和稳健的方法，用于发现具有非天然肽的新结构和功能的从头 DRP，

  DOI：

  10.1021/jacs.2c00216
• 作为产物：
  描述：

  (S)-3-Benzylamino-2-tert-butoxycarbonylamino-propionic acid 在 1,4-环己二烯 、 palladium 10% on activated carbon 、 碳酸氢钠 作用下， 以 1,4-二氧六环 、 乙醇 、 水 为溶剂， 生成 (S)-2-(Boc-氨)-3-(Fmoc-氨)丙酸
  参考文献：
  名称：

  从 d-丝氨酸获得的 2,3-二氨基丙醇作为合成受保护的 2,3-l-二氨基丙酸 (l-Dap) 甲酯的中间体

  摘要：

  开发了一种用于制备非蛋白氨基酸 2,3-l-二氨基丙酸 (l-Dap) 的两个正交保护甲酯的合成策略。在这些结构中，碱不稳定保护基团 9-芴基甲氧羰基 (Fmoc) 与对甲苯磺酰基 (tosyl, Ts) 或酸不稳定的叔丁氧羰基 (Boc) 部分配对。受保护的 l-Dap 甲酯的合成方法使用适当掩蔽的 2,3-二氨基丙醇，这是通过对由商业氨基酸 Nα-Fmoc-O-叔丁基-d-丝氨酸制备的醛进行还原胺化获得的，用作起始材料。还原胺化是用伯胺和磺酰胺进行的，该过程由路易斯酸 Ti(OiPr)4 辅助。通过氧化2的醇官能团来安装所需的羧基，在 3-NH2 位点带有甲苯磺酰基或苄基保护基团的 3-二氨基丙醇。使用每个步骤后获得的粗产物可以轻松应用该程序，最大限度地减少色谱纯化的需要。起始 d-丝氨酸模板的碳原子手性在所有合成步骤中均保持不变。

  DOI：

  10.3390/molecules25061313

文献信息

• [EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS
  申请人：FOGHORN THERAPEUTICS INC

  公开号：WO2019152437A1

  公开（公告）日：2019-08-08

  The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

  本公开涉及用于治疗BAF复合物相关疾病的化合物。
• PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING
  申请人：Purdue Research Foundation

  公开号：US20160067341A1

  公开（公告）日：2016-03-10

  Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

  本文描述了用于传递治疗、诊断和成像剂的前列腺特异性膜抗原（PSMA）结合共轭物。本文还描述了含有它们的药物组合物以及使用这些共轭物和组合物的方法。还描述了用于制造这些共轭物和含有它们的组合物的过程。
• METHODS OF TREATING CANCER WITH A PSMA LIGAND-TUBULYSIN COMPOUND
  申请人：ENDOCYTE, INC.

  公开号：US20180036364A1

  公开（公告）日：2018-02-08

  The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating PSMA expressing cancers with a PSMA ligand-tubulysin compound. The invention described herein also relates to methods of treating PSMA-expressing cancers with a PSMA ligand-tubulysin compound in patients where stable disease results after treatment with the PSMA ligand-tubulysin compound.

  本发明涉及用于靶向治疗的药物传递共轭物。本发明涉及使用PSMA配体-管芋霉素化合物治疗表达PSMA的癌症的方法。本发明还涉及在接受PSMA配体-管芋霉素化合物治疗后出现稳定疾病的患者中治疗表达PSMA的癌症的方法。
• Synthesis and study of peptides with semirigid i and i+7 side-chain bridges designed for α-helix stabilization
  作者：Chongxi Yu、John W. Taylor

  DOI：10.1016/s0968-0896(98)00232-6

  日期：1999.1

  consisted of a 4-(aminomethyl)phenylacetic acid residue (AMPA) linked by amide bonds to the side chain functional groups of a (S)-2,3-diaminopropionic acid residue (Dap) in position 3 of the model peptide and an aspartic acid residue in position 10. This Dap3(AMPA), Asp10 bridge was about as effective as two Lys(i), Asp(i+4) lactam bridges incorporated linking residues 3 and 7, and 10 and 14, in the same

  对肽α-螺旋构象的构象限制的搜索表明，苯环的对位取代的氨基酸衍生物可能适用于连接成对的侧链对，所述成对的侧链被螺旋的两个匝隔开。已使用14个残基的合成两亲性α-螺旋肽模型系统来研究一系列四个具有结构异构结构的此类桥的螺旋稳定作用。这些桥用于连接模型肽的3和10位。通过标准固相方法，包括在固相支持物上的环化，以高收率合成了这些肽。然后通过圆二色性（CD）光谱极化法研究它们的溶液构象和熔融行为，以及在反相HPLC柱上的洗脱行为。在水溶液和50％（v / v）的三氟乙醇中，最有效的螺旋稳定桥由通过酰胺键连接至（S）侧链官能团的4-（氨基甲基）苯基乙酸残基（AMPA）组成模型肽第3位的-2,3-二氨基丙酸残基（Dap）和第10位的天冬氨酸残基。该Dap3（AMPA），Asp10桥与两个Lys（i），Asp（i + 4）内酰胺桥在相同模型肽序列中掺入连接残基3和7、10和14。这表明其价值约为1 kcal
• HCV PROTEASE INHIBITORS AND USES THEREOF
  申请人：Niu Deqiang

  公开号：US20090176858A1

  公开（公告）日：2009-07-09

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供了化合物、药学上可接受的组合物以及使用它们的方法。